enzalutamide
2 stories
-
healthDarolutamide Shows Cognitive Edge Over Enzalutamide in Prostate Cancer
New data from the ARACOG trial shows darolutamide causes less cognitive decline than enzalutamide in prostate cancer patients.
-
healthTALAPRO-3 Shows PARP Inhibitor Combo Delays Prostate Cancer Progression
Phase 3 trial results presented at ASCO 2026 show talazoparib plus enzalutamide significantly improves radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.